Crinetics Pharmaceuticals Inc CRNX
84.95 USD 0.00 (+0.00%)
At closeAug 31, 2026, 4:00 PM EDT
37.84 -47.11 -55.46%
After hours · Aug 31, 4:00 PM ET
84.92 Day range 85.01
32.30 52-week range 85.01
- YTD
- +82.49%
- 1 year
- +183.26%
Analyst view
Consensus: hold
Hold
Price target (mean) 85.00
Ratings (0m) 9 1 buy · 8 hold · 0 sell
- Strong buy0
- Buy1
- Hold8
- Sell0
- Strong sell0
Recommendation trend
- This month 9
- 1 month ago 14
- 2 months ago 14
- 3 months ago 16
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -1.13 | -1.26 – -0.88 | -1.38 | +17.8% | 41.69M | +29053.8% | 8 |
| Next quarter | -1.07 | -1.25 – -0.80 | -1.29 | +17.0% | 84.31M | +1268.5% | 8 |
| Current year | -4.54 | -4.99 – -3.48 | -4.95 | +8.3% | 161.85M | +2003.1% | 8 |
| Next year | -4.01 | -5.12 – -2.48 | -4.54 | +11.6% | 178.61M | +10.3% | 7 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 28, 2026 | UBS | Downgrade | Buy | Neutral |
| Jul 8, 2026 | TD Cowen | Downgrade | Buy | Hold |
| Jul 8, 2026 | Evercore ISI Group | Downgrade | Outperform | In-Line |
| Jul 7, 2026 | Jones Trading | Downgrade | Buy | Hold |
| Jul 7, 2026 | Jefferies | Downgrade | Buy | Hold |
| Jul 7, 2026 | Oppenheimer | Downgrade | Outperform | Perform |
| Jul 7, 2026 | Cantor Fitzgerald | Downgrade | Overweight | Neutral |
| Jul 7, 2026 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| Jul 7, 2026 | Baird | Maintained | Outperform | Outperform |
| Jul 2, 2026 | UBS | Initiated | — | Buy |
| Jun 15, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jun 11, 2026 | Citizens | Reiterated | Market Outperform | Market Outperform |
| May 15, 2026 | Evercore ISI Group | Maintained | Outperform | Outperform |
| May 11, 2026 | Oppenheimer | Maintained | Outperform | Outperform |
| May 8, 2026 | Citizens | Maintained | Market Outperform | Market Outperform |
| Apr 28, 2026 | Citizens | Maintained | Market Outperform | Market Outperform |
| Mar 2, 2026 | Citizens | Maintained | Market Outperform | Market Outperform |
| Jan 12, 2026 | Goldman Sachs | Upgrade | Neutral | Buy |
| Jan 8, 2026 | Citizens | Maintained | Market Outperform | Market Outperform |
| Jan 6, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Nov 7, 2025 | Citizens | Maintained | Market Outperform | Market Outperform |
| Sep 30, 2025 | Oppenheimer | Maintained | Outperform | Outperform |
| Sep 29, 2025 | Morgan Stanley | Maintained | Overweight | Overweight |
| Sep 29, 2025 | Leerink Partners | Maintained | Outperform | Outperform |
| Sep 26, 2025 | Goldman Sachs | Maintained | Neutral | Neutral |
| Sep 26, 2025 | JMP Securities | Maintained | Market Outperform | Market Outperform |
| Sep 26, 2025 | Baird | Maintained | Outperform | Outperform |
| Sep 24, 2025 | JP Morgan | Maintained | Overweight | Overweight |
| Aug 11, 2025 | JMP Securities | Maintained | Market Outperform | Market Outperform |
| Jun 27, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |